Skip to main content

GSK to Use Response Genetics' PCR Technology to Develop Companion Diagnostics for Cancer Drugs


GlaxoSmithKline has licensed non-exclusive rights to Response Genetics' PCR technology and "diagnostic expertise" to assess BRAF gene mutations in human tumor samples. The drug company intends to apply the technology to develop companion diagnostics for BRAF and MEK inhibitors currently under development.

GSK's drug development pipeline, updated as of February, indicates the company has a BRAF protein kinase inhibitor and a MEK inhibitor. Both are in Phase II trials and are being developed as treatments for cancer.

Los Angeles-based Response Genetics said that it will receive certain agreed-to milestone payments from GSK, but did not provide details of its financial agreements with the drug developer.

Kathleen Danenberg, president and CEO of Response Genetics, noted that the firm already provides GSK with genetic testing services to support its drug development programs.

However, the present deal with GSK around its PCR technologies is independent of the companies' already existing relationship, a GSK spokesman told Pharmacogenomics Reporter.

In 2008, the companies inked a deal to conduct gene-expression screening studies for a Phase III trial of GSK's investigational MAGE-A3 antigen-specific immunotherapeutic for non-small cell lung cancer.

GSK would not discuss the specific PCR technology platform the company has licensed from Response under the partnership, nor whether this partnership extends to the commercial development of companion tests.

Response Genetics sells its ResponseDX: Colon, ResponseDX: Lung, and ResponseDX: Gastric genetic test panels in the US directly and through an agreement with NeoGenomics Laboratories inked in September 2008. All of the tests are performed at Response Genetics' CLIA-certified lab.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.